| Jessica T Chu, MD | |
|
10310 The Grove Blvd, Baton Rouge, LA 70836-6455 | |
| (225) 761-5200 | |
| Not Available |
| Full Name | Jessica T Chu |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 8 Years |
| Location | 10310 The Grove Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447612320 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 312827 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Medical Center - Baton Rouge | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
Bion Environmental Technologies, Inc. announced today that it has been notified by the United States Patent and Trademark Office that the patent application entitled "Micro-Electron Acceptor Phosphorus Accumulating Organisms" has been granted.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.
Five times a day, roughly 1.6 billion Muslims worldwide, bow, kneel, and place their foreheads to the ground in the direction of the holy city of Mecca, Saudi Arabia, as part of the Islamic prayer ritual, the Salat. The ritual is one of the five obligatory elements of the faith set forth by the holy book, the Qur'an.
A new meta-analysis, published in The Lancet Diabetes & Endocrinology journal, concludes that there is no evidence to suggest that vitamin D supplements prevent falls, and that ongoing trials to test this theory are unlikely to change this result.
Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
› Verified 7 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Bion Environmental Technologies, Inc. announced today that it has been notified by the United States Patent and Trademark Office that the patent application entitled "Micro-Electron Acceptor Phosphorus Accumulating Organisms" has been granted.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.
Five times a day, roughly 1.6 billion Muslims worldwide, bow, kneel, and place their foreheads to the ground in the direction of the holy city of Mecca, Saudi Arabia, as part of the Islamic prayer ritual, the Salat. The ritual is one of the five obligatory elements of the faith set forth by the holy book, the Qur'an.
A new meta-analysis, published in The Lancet Diabetes & Endocrinology journal, concludes that there is no evidence to suggest that vitamin D supplements prevent falls, and that ongoing trials to test this theory are unlikely to change this result.
Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica T Chu, MD 10310 The Grove Blvd, Baton Rouge, LA 70836-6455 Ph: (225) 761-5200 | Jessica T Chu, MD 10310 The Grove Blvd, Baton Rouge, LA 70836-6455 Ph: (225) 761-5200 |
News Archive
Bion Environmental Technologies, Inc. announced today that it has been notified by the United States Patent and Trademark Office that the patent application entitled "Micro-Electron Acceptor Phosphorus Accumulating Organisms" has been granted.
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.
Five times a day, roughly 1.6 billion Muslims worldwide, bow, kneel, and place their foreheads to the ground in the direction of the holy city of Mecca, Saudi Arabia, as part of the Islamic prayer ritual, the Salat. The ritual is one of the five obligatory elements of the faith set forth by the holy book, the Qur'an.
A new meta-analysis, published in The Lancet Diabetes & Endocrinology journal, concludes that there is no evidence to suggest that vitamin D supplements prevent falls, and that ongoing trials to test this theory are unlikely to change this result.
Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.
› Verified 7 days ago
Lauren Kathryn Petit, MD Dermatology Medicare: Medicare Enrolled Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-246-9790 Fax: 225-246-9160 | |
Tom J Meek Jr., MD Dermatology Medicare: Medicare Enrolled Practice Location: 5326 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Jordan Lynn Whatley, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5326 Odonovan Dr, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Dr. Azeen Sadeghian, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8585 Picardy Ave Ste 512, Baton Rouge, LA 70809 Phone: 253-333-6142 | |
Dr. Harry A Burglass Jr., MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5326 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-769-7546 Fax: 225-769-0471 | |
Sarah Mcginty, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10154 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-5663 Fax: 225-928-7341 | |
Courtney Murphy, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-769-4044 |